Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Prostatic Neoplasms

• Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer
• Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
• Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
• Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
• Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
• Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
• Telmisartan in Prostate Cancer
• A Phase I Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
• MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
• Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
• A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
• Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
• Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
• Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
• Combination Study of Antibiotics With Enzalutamide (PROMIZE)
• Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
• Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
• The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer
• The University of Miami Adapt (UAdapt) Trial
• Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
• A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
• Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413
• Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
• Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
• Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
• Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
• A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
• Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
• Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy
• Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
• A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
• Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
• Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer
• PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
• Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
• NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
• Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
• Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer
• Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
• Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
• Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
• Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer
• A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-re
• TmPSMA-02 in mCRPC
• A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
• Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
• Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
• A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer
• Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
• Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
• Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
• A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.
• Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
• IS-002 in Prostate Cancer
• HTL0039732 in Participants With Advanced Solid Tumours
• Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
• A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
• Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
• A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
• Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
• A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
• Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
• A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
• Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
• Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Pancreatic Cancer Patients Undergoing Treatment With ADT Combination Therapy
• Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
• Dose Escalation For INtraprostatic LEsions
• Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
• A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
• 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
• Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
• High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
• Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
• SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer
• PSMA PET Scan and mpMRI for Prostate Cancer Detection
• A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer
• Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy
• 177Lu-labeled NY108 SPECT Imaging in Patients
• 18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
• PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study
• Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
• Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
• Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain
• Akkermansia Muciniphilia and Metabolic Side Effects of ADT
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
• Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
• Measuring Oncological Value of Exercise and Statin
• A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Nonmetastatic Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
• Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer
• DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
• Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
• Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
• Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer
• Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
• Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
• RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
• Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
• Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
• Laparoscopic TAP Block During Robotic Assisted Laparoscopic Radical Prostatectomy for Improvement in Postoperative Pain
• Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
• Ga-68-PSMA-11 in Men With Prostate Cancer
• Phase I Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
• A Phase I Clinical Study of HS-10502 in Patients With Advanced Solid Tumors
• Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
• Vudalimab in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
• PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
• Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study
• A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
• Phase 0/1 Study of 212Pb-NG001 in mCRPC
• Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
• Dose Escalation and Efficacy Study of 212Pb-ADVC001 in Patients With Metastatic Castration Resistant Prostate Cancer.
• Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment
• A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
• Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
• 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study
• Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
• Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
• CJNJ-67652000 and Prednisone for the Treatment of Men With Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
• Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
• Phase 2 Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
• A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
• Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence
• Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
• MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
• A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
• A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
• A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
• CART-PSMA Cells for Advanced Prostate Cancer
• Checkpoint Inhibitors and SBRT for mCRPC
• Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
• A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3
• Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer
• 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
• Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
• 68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
• Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
• 68Ga-labeled NY108 PET Imaging in Patients
• Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
• Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
• A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
• Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
• Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)
• 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
• A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
• 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
• Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
• Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
• Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
• T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
• MDPK67b in Patients With Prostate Cancer
• [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2
• A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer
• 177Lu-HTK03170 in mCRPC With PSMA Positive Disease
• Pembro With Radiation With or Without Olaparib
• Prostate MRI and Pylarify PSMA PET/CT
• ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer
• A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer
• Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
• Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
• Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
• Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
• Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
• Tracer-Guided Surgery for Recurrent Prostate Cancer
• MGC018 Versus Androgen Receptor Axis-targeted Therapy in Participants With Metastatic Castration Resistant Prostate Cancer
• The Effects of Polaprezinc Combined With AR-inhibitors on Patients With CRPC
• 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
• A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
• Investigator Initiated Trial of Syncrovax - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
• Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
• A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
• A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
• EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
• 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
• CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours
• Study of 18F-Thretide PET/CT in Patients With Suspected Recurrence of Prostate Cancer
• Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
• Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
• Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
• Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
• 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
• Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors
• Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
• ArtemiCoffee in Patients With Rising PSA
• Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
• The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer
• Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
• [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
• Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
• Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer
• A Phase II Study of N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
• Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
• A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
• Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
• Study of ORIC-944 in Patients With Metastatic Prostate Cancer
• 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
• Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
• To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer
• Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
• Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
• Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II Study
• A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer
• AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
• Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
• A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
• Metastasis-directed Therapy for Oligorecurrent Prostate Cancer: a Randomized Phase III Trial
• A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Pr
• Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
• A Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
• Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
• An Imaging Agent (Perflutren Lipid Microspheres) With Ultrasound for Imaging of Prostate Cancer
• Safety, Tolerability and PK Evaluation of BZ371A, Topically Administered
• Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
• 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Cancer Patients
• RElugolix VErsus LeUprolide Cardiac Trial
• Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.
• A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
• Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
• Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib
• The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation
• A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
• A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer
• Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
• 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
• PET Imaging Study of 89Zr-DFO-YS5
• A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
• Radioligand fOr locAl raDiorecurrent proStaTe cancER
• TERPS Trial for de Novo Oligometastic Prostate Cancer
• Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
• Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST).
• Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
• Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
• 68Ga-PSMA-11 PET in Patients With Prostate Cancer
• Therapeutics in Active Prostate Cancer Surveillance (TAPS02)
• Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
• First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
• Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
• Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
• A Study to Learn More About Darolutamide Compared to Placebo in Addition to Androgen Deprivation Therapy, a Treatment That Lowers Hormones Called Androgens in Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
• A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
• Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
• The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation
• EBRT + Lu-PSMA for N1M0 Prostate Cancer
• A Study of PRT2527 in Patients With Advanced Solid Tumors
• Phase 2 Trial of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
• TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
• Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
• 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION)
• Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
• A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
• A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
• REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer
• IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
• Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
• Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy
• Pioglitazone and Insulin Resistance in ADT
• Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
• A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
• Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
• Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer
• EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC
• Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
• Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer
• A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
• Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
• Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
• Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
• A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
• Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block
• SRT Versus SRT+ADT in Prostate Cancer
• High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
• FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
• A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
• Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis
• Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
• An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
• Therapeutic Efficiency and Response to 177Lu-EB-PSMA-617 in Comparison to 177Lu-PSMA-617 in Patients With mCRPC
• Insulin Resistance and Androgen Deprivation Therapy
• A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
• The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
• Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
• ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
• Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
• An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
• Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
• A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
• 68Ga-PSMA PET/CT for Ra223 Assessment
• Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
• Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
• Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-Ch
• SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy
• 11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer
• Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
• The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer
• Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
• The Effect of Metformin in Patients With Newly Diagnosed mHSPC
• Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer
• ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability
• Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
• PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
• Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
• A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
• Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer
• A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers
• Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
• TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
• 225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC
• Use of Indocyanine Green During Pelvic Lymph Node Dissection in Prostate Cancer.
• Phase 1 Study of ATRS-2002 in Healthy Male Adults
• MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
• The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
• A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
• Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
• 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
• Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions
• Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer
• 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
• Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
• Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
• Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
• Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
• Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)
• PK, PD, Tolerability and Safety of MDPK67b in Healthy Volunteers
• The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC
• Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
• Study of Diagnostic Performance of [18F]CTT1057 in BCR
• Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
• Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients
• 68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
• Telaglenastat + Talazoparib In Prostate Cancer
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
• Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
• 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
• Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer
• To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers
• Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
• An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
• The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients
• Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients With Prostate Cancer.
• PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
• Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
• Abemaciclib With or Without Atezolizumab for mCRPC
• Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
• Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
• A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
• Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer
• Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
• Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
• Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
• Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
• Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
• 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
• 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC
• 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
• A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
• Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
• A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
• PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
• Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
• [Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
• A Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
• 68Ga-PSMA PET/CT in Prostate Cancer
• Study of PCUR-101 in Combination With ADT in Patients With mCRPC
• SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
• Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
• Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
• 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
• ARX517 in Subjects With Advanced Solid Tumor
• Insulin Resistance Following ADT for Prostate CA
• Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
• A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
• Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer
• Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
• Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
• Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
• Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
• Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
• A Study of CC-90011 and Comparators in Participants With Prostate Cancer
• Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT
• Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome
• Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
• 68 Ga-PSMA for High Risk Prostate Cancer
• A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
• Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan
• Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
• Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer
• To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
• Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
• Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
• Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
• Re-treatment 225Ac-J591 for mCRPC
• A Study of FT-7051 in Men With MCRPC
• A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy
• Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy
• Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients
• Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
• PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer
• Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants
• PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
• Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
• Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
• Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin
• [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
• A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
• A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
• White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
• Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
• [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.
• Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastati
• A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
• Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
• Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
• SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation
• Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
• 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
• Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
• ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
• Impact of Acetazolamide in Reducing Referred Postoperative Pain
• EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
• High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
• Abiraterone Acetate in Combination With Tildrakizumab
• A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
• Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
• Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
• Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer
• Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
• Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging
• Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
• Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
• Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
• Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
• A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
• Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate
• Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
• 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
• PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
• Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
• Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
• Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
• Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
• In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
• 18F-fluorocholine and 18F-fluoride PET in Prostate Cancer
• Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
• Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
• Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
• Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
• Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
• Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
• Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
• Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
• Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
• Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
• PK and Dose Escalation and Expansion Study of DST-2970
• Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
• Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
• Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
• Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
• Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand
• HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
• Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
• Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
• P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
• Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
• PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
• Long-term Better Than Short-term ADT With Salvage RT
• A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
• A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
• Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
• Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
• Trial of NanoPac Focal Therapy for Prostate Cancer
• Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
• Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer
• 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
• Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
• Radium-223 in Biochemically Recurrent Prostate Cancer
• A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
• 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
• Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)
• Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)
• Recommended Dose Estimation of BP-C2
• Cardiovascular Events in GnRH Agonist vs. Antagonist
• Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
• The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
• Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy
• Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
• PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
• Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
• The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
• ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
• 68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
• 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
• A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Metastatic Solid Tumors
• Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
• A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer
• A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
• Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
• Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
• Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
• An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
• The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer
• Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
• Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
• Safety and Targeting of Anti-hk2 Antibody in mCRPC
• Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
• Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
• Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
• A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC
• A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
• A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
• A Study of CPI-0209 in Patients With Advanced Tumors
• the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma
• F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
• A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
• A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
• A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
• A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
• pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
• An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
• A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
• PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study
• National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients
• Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
• First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
• An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Horm
• Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
• Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
• Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer
• Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
• Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
• Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
• 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
• Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
• RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
• Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer
• Study of ORIC-101 in Combination With Enzalutamide
• Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
• Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
• ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
• Impact of Atorvastatin on Prostate Cancer Progression During ADT
• INTREPId (INTermediate Risk Erection PreservatIon Trial)
• Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
• A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
• PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
• Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
• Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
• Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
• Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone
• The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
• Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
• Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
• A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
• Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
• Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer
• REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
• A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy
• Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
• Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
• SRAM study_Postate Cancer
• Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer
• CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
• Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
• Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects
• A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
• ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer
• Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
• Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
• the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer
• Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
• Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
• Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
• A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
• Safety and Pharmacokinetics of ODM-209
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
• The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer
• 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
• PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
• Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
• Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
• Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
• A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
• Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
• 18F-DCFPyL PET-CT Scan and Prostate Cancer
• A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
• HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer
• EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.
• A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
• A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
• A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
• Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
• Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
• Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
• Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
• Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
• TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
• Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
• Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
• 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
• A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
• Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
• Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
• Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy
• Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
• VAccination in Early and ADvanced Prostate caNCEr
• A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
• A Study of Olaparib and Durvalumab in Prostate Cancer
• A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
• A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
• The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
• Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
• Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
• (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes
• Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
• Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
• Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
• SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
• Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer
• A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
• Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
• A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
• A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
• Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer
• Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
• Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
• PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
• A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
• Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide
• Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
• Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
• A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
• Initiative to Minimize Disparities in Postoperative Prostate Cancer Care
• Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
• To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
• Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
• A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
• Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
• Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
• Testosterone Therapy in Castration Resistant Prostate Cancer
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
• IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
• Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
• Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
• Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
• Study of Chitosan for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients
• Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
• Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
• TUPKRP Combined With MAB Therapy for LUTS/PCa
• 4-aminopyridine Treatment for Nerve Injury
• Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
• Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
• Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
• An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
• Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
• Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
• PSMA Imaging of Localized Prostate Cancer
• Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
• PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
• Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
• Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
• Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
• Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
• A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
• Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
• Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients
• Comparison of PET With 68GA-PSMA-11 and 18F-Fluorocholine for Recurrence in Men With Prostate Cancer
• Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
• Trial of eRapa in Prostate Cancer Patients
• 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer
• Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia
• 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging
• 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
• Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study
• pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
• This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
• Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
• Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
• Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
• Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency
• A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
• Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
• A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
• Hypofractionated Radiation Therapy in Treating Participants With Prostate Cancer High-Risk Features Following Radical Prostatectomy
• Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
• Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
• PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
• Study to Evaluate CCS1477 in Advanced Tumours
• Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
• FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
• Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
• COMbination of Bipolar Androgen Therapy and Nivolumab
• A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
• 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
• Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
• Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
• Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
• Muscadine Plus (MPX) In Men With Prostate Cancer
• Rucaparib in Nonmetastatic prOstAte With BRCAness
• Nutrition and Prostate Cancer
• Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
• Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
• Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing RALP
• Effect of Yoga Counselling on Quality of Life and Psychological Outcomes of Prostate Cancer Patients
• A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
• An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
• Bipolar Androgen Therapy + Carboplatin in mCRPC
• A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
• M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
• Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
• A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer
• Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
• A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer
• Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer
• Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
• Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
• A Study of IMP4297 in Patients With Advanced Solid Tumors
• The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
• Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
• Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR)
• Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
• Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
• PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
• Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
• 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
• 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
• Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
• ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
• Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
• Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
• Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
• Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients
• PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
• Pre-Operative Single Shot Rectus Sheath Block
• Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
• Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer
• Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
• ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
• Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
• CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
• A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
• Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)
• Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
• Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
• Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
• Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose
• Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
• Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
• The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
• Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
• Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
• Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)
• Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC
• BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes
• Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer
• A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
• Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
• Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
• Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
• Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
• Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
• A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
• 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
• Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
• A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
• PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
• 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
• 68Ga PSMA in Preprostatectomy Patients
• Prostate Cancer Biomarker Enrichment and Treatment Selection
• Prostate Boost Irradiation With Stereotactic Body RT (SBRT)
• A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer
• BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
• Therapeutics in Active Prostate Cancer Surveillance
• Ga-68-PSMA-11 in High-risk Prostate Cancer
• Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.
• Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
• Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
• A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
• Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
• CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
• Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate
• Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
• A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer
• Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
• Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
• An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
• Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients
• Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
• Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
• Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
• Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
• A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
• The Effect of ADT on PSMA-PET.
• A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
• AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
• Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
• uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness
• The Combination Therapy With Ra-223 and Enzalutamide
• Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
• ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
• Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
• Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation
• Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
• Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
• Phase I Trial of 225Ac-J591 in Patients With mCRPC
• Cisplatin in Castration Resistant Prostate Cancer
• Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
• Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
• Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
• High Resolution PET-MRI Before Prostate Cancer HIFU
• Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
• Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
• Oral Calcitriol With Ketoconazole in CRPC
• A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis
• Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
• Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
• A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
• Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
• PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
• Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position
• Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
• Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
• A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone
• Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer
• AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
• Tremelimumab + Durvalumab Chemotherapy Naive CRPC
• PSMA PET Imaging of Recurrent Prostate Cancer
• Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
• Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer
• Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
• 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
• PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
• Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
• Combination Study of AZD5069 and Enzalutamide.
• 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
• Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
• 68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients
• Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
• Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
• A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
• Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
• Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
• A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
• Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer
• ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
• Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
• Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
• Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
• 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
• Phase I Trial of PACE for Metastatic Prostate Cancer
• A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
• A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression
• Multiparametric Ultrasound Imaging in Prostate Cancer
• Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic
• Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer
• Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
• A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
• CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
• Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer
• A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
• Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
• Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
• Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
• Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
• A Study Evaluating MM-310 in Patients With Solid Tumors
• Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
• Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer
• Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
• INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
• Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
• Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
• Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System
• Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
• An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
• Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
• Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
• Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
• Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
• Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
• A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
• Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
• Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
• Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer
• Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
• Neoadjuvant Listeria or Daratumumab in Prostate Cancer
• A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
• Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
• Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
• A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refus
• Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
• A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
• Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
• Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
• Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer
• 68Ga-PSMA PET/CT in Prostate Cancer
• Combination Study of Guadecitabine and Pembrolizumab.
• Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
• Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
• Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
• Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
• Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
• Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
• A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
• ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
• Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
• uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
• A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
• One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™
• Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
• The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
• A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
• Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
• A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
• Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
• Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
• SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
• Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate
• Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
• ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
• PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
• PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.
• A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
• Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
• Multicentre Biomarker Study in CRPC Treated With Enzalutamide
• 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated
• Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
• Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
• A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
• Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer
• Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
• Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
• Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer
• Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
• Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy
• A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
• Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
• Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
• Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
• PSMA PET/CT for Assessment of Recurrent Prostate Cancer
• Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
• Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
• Safety and Efficacy of Firmagon® (Degarelix) for Injection
• Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake
• Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
• PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
• Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
• Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)
• Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
• Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
• An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
• The Role of C-11 Choline PET in Patients With Prostate Cancer
• A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
• A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
• Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• ICG-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes
• The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer
• Pre-Prostatectomy Celecoxib or Placebo
• Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
• Effect of Intravenous Magnesium During Robot Assisted Prostatectomy
• FACBC Prostate Therapy Response
• Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer
• C11 Sodium Acetate PET/CT Imaging of PCa
• Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer
• Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
• Preoperative Brimonidine on IOP of Patients Undergoing RALP
• 11C or 18F-Choline PET/CT and Whole Body MRI for Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
• 18F-FDG PET/CT and Whole Body MRI for Staging and Response Prediction in Castration-resistant Prostate Cancer Patients Receiving Enzalutamide
• Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
• Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
• Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management
• 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
• Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
• NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
• Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer
• Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
• A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
• Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
• ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
• Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
• Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer
• Correlation Between SUV on 18F-Fluorocholine PET/CT and Gleason Score in Prostate Cancer
• Docetaxel Followed by Provenge in Metastatic Prostate Cancer
• Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
• Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
• Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
• Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Abiraterone
• Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
• Reducing Dexamethasone Around Docetaxel Infusion
• AASUR in High Risk Prostate Cancer
• Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
• Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
• Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
• Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer
• Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
• Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
• Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
• A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
• 68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer Patients
• Targeted Fusion Biopsy of the Prostate
• Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
• Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
• A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
• Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer
• Treatment Patterns in Metastatic Prostate Cancer
• Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy
• A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
• Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)
• Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
• 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
• Evaluation of Safety and Efficacy of Estetrol in Healthy Men
• A Study of Definitive Therapy to Treat Prostate Cancer
• C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer
• Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
• A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
• A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
• Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
• Neoadjuvant J591 Treatment for Prostate Cancer
• A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
• Integrated 18F-labelled PSMA Project
• Management of Castration-Resistant Prostate Cancer With Oligometastases
• Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer
• Stereotactic Body Radiation for Prostate Oligometastases
• 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
• Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
• 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
• A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
• 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
• Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
• A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
• PET/MRI in Patients With Suspected Prostate Cancer
• Abiraterone-Rechallenge Study for CRPC Patients
• Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients
• Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
• Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
• Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
• Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
• Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer
• Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
• Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
• Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
• Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET
• Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.
• Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs
• A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
• Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer
• Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
• Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
• Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
• A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
• Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
• Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer
• Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
• Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)
• A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
• The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
• Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide
• Tumor Hypoxia With HX4 PET in Several Diseases
• Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
• Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
• A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
• Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
• Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
• Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
• Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression
• J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
• Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
• Effect of Dexmedetomidine on Heart-rate Corrected QT(QTc) Interval Prolongation During Robotic-assisted Laparoscopic Radical Prostatectomy -Randomized Blind Clinical Trial-
• Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal
• Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
• Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography
• An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
• A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
• Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
• A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
• Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
• Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
• Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
• Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
• Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer
• Metformin And Longevity
• Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
• Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
• Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
• Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC
• Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
• Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
• A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
• LIpitor and biGuanide to Androgen Delay Trial
• European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
• LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
• Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
• Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
• Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
• 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
• Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer
• Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
• Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
• PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
• A Study of Pertuzumab in Participants With Prostate Cancer
• Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
• Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
• PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
• Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
• Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
• Carbon-11 Labeled Sarcosine in Prostate Cancer
• Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
• Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
• Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
• Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
• Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
• MRI With C13 Pilot Study Prostate Cancer
• Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
• Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
• Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
• Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer
• A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
• A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
• Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
• Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA
• Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
• Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
• Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
• Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
• AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)
• Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
• A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
• A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
• Discovery Stage IND EXEMPT Clinical Study About ABIRATERONE ACETATE and Single Nucleotide Polymorphisms
• Comparison Between Conventional and Model-based Infusion Strategy of IV PCA in Patients Undergoing RALP
• Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
• 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer
• A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
• Gallium-68 Citrate PET Used in Prostate Cancer
• Vaccination in Prostate Cancer (VANCE)
• A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
• Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy
• G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
• Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide
• A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC
• Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients
• Metformin for Rising PSA Remote Trial
• Micro RNAs to Predict Response to Androgen Deprivation Therapy
• Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects
• A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
• Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
• Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
• Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
• A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).
• Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
• Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
• A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
• High-Dose Brachytherapy in Treating Patients With Prostate Cancer
• Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer
• A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer
• Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer
• ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer
• Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
• Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
• Carboplatin in Castration-resistant Prostate Cancer
• Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
• [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
• Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
• An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
• Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer
• A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
• Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
• 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
• Dose Finding Safety Study of VAL201 in Cancer Patients
• Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
• Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
• Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
• Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
• Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
• Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
• A Phase 1 Study Evaluating the Safety, PK, and Clinical Effects of PT-112 in Subjects With Advanced Solid Tumors
• A Study of LY3022855 In Participants With Breast or Prostate Cancer
• Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
• Interest of Indocyanine Green in Neoplastic Prostatic Tissue
• An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRP
• EXTEND Exercise Trial
• Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
• Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy
• Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
• Pilot Study of DRibble Vaccine for Prostate Cancer Patients
• Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
• Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
• A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
• Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2
• Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
• Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
• Radium-223 in Combination With Enzalutamide
• A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
• Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
• Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
• Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
• Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
• Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
• Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
• Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
• Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
• Molecular Phenotype Changes and Personalized Treatment for CRPC
• Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
• Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer
• BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
• Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
• Phase 1 of EC1169 In Patients With Recurrent MCRPC
• Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
• Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
• Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer
• Phase III Radium 223 mCRPC-PEACE III
• 18F-DCFBC PET/CT in Prostate Cancer
• Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
• LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
• Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
• A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
• Metformin Prostate Cancer Adjuvant Trial
• Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
• Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
• Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"
• A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
• Neo-adjuvant Abiraterone Prostate Study
• Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
• Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
• The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide
• A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
• SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
• A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
• A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer
• Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
• Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
• Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
• Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
• An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation
• Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
• Sequencing Abiraterone and Enzalutamide in mCRPC
• Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
• A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
• A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
• Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy
• Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery
• A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
• A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
• T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
• Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
• A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer
• Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
• ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
• Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
• MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
• Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
• Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
• Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)
• Prostate Hypoxia - TIC
• Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
• Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
• RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
• A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
• A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
• Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)
• Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
• A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
• Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
• Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer
• Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
• Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
• A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
• LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
• Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
• Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
• A Safety and Feasibility Study of Mitotane in Prostate Cancer
• Sulforadex in Healthy Human Males MAD
• Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)
• Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
• Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
• Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
• Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
• Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
• Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Che
• A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
• To Evaluate the Effect of MCS® in Prostate Cancer Prevention
• Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
• Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.
• Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel
• A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
• Enzalutamide + External Beam Rt For Prostate
• Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy
• Trial of Abiraterone Without Exogenous Glucocorticoids in Men With CRPC With Correlative Assessment of Hormone Intermediates.
• Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
• Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
• Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer
• An Open-label Extension Study of PSMA ADC 2301 in mCRPC
• Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical
• An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
• Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
• A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
• Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
• Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
• A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function
• Prothrombotic Factors and Anaesthesia in Prostate Cancer
• Improving Erectile Function and Quality of Life After Prostate Cancer Treatment
• Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
• Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
• Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
• Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
• Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
• 18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer
• Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer
• A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
• Intrathecal Morphine in Robot-assisted Prostatectomy
• Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
• The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation
• A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
• Efficacy Study Evaluating Chemotherapy in Prostate Cancer
• A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
• Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
• A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
• Abiraterone Acetate for Castrate Resistant Prostate Cancer
• A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
• A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
• Docetaxel and Lycopene in Metastatic Prostate Cancer
• Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
• Sulforadex in Healthy Volunteers SAD
• A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
• Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
• Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling
• Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
• Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate
• Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
• A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
• Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
• 18F-NaF PET Imaging for Bone Scintigraphy
• Japanese BAY88-8223 Monotherapy Phase II Study
• Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
• Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
• Enzalutamide in Patients With High-risk Prostate Cancer
• HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
• Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer
• Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
• A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
• Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
• A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).
• Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
• Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer
• Tivozanib + Enzalutamide in Adv Prostate Cancer
• AZD8186 First Time In Patient Ascending Dose Study
• Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients
• Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer
• Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
• Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
• Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
• Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
• Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• The Metformin Active Surveillance Trial (MAST) Study
• Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours
• Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
• Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate
• Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
• Degarelix Before Radical Prostatectomy
• Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
• Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
• Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer
• A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
• A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
• Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
• A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
• Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
• Study of Dasatinib, Androgen Deprivation Therapy and Radiation
• Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery
• Atorvastatin Before Prostatectomy and Prostate Cancer
• Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
• NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
• Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer
• A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
• Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
• Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
• FACBC for Recurrent Prostate Cancer
• Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
• Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
• Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO)
• A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
• Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer
• A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
• Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
• Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
• A Phase I Trial of AZD3965 in Patients With Advanced Cancer
• The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
• Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
• Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
• Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer
• Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
• Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan
• Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
• Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer
• Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial
• A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
• A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
• 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
• Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
• Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
• Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer
• One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
• A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy
• BKM120+Abiraterone Acetate for Metastatic CRPC
• Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
• Abiraterone Acetate Trial in African American Prostate Cancer Patients
• Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
• Prostate Cancer Active Surveillance Metformin Trial
• A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
• Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
• Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation
• Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT
• Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
• [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
• Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
• A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
• Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
• Treatment of Prostate Cancer With Firmagon®
• A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
• Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
• Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients
• Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer
• Cabozantinib in Men With Castration-Resistant Prostate Cancer
• Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
• A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
• Neoadjuvant BKM120 in High-risk Prostate Cancer
• A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
• A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
• Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
• Mild Cognitive Impairment in Men Following Androgen Deprivation
• Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
• Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance
• A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
• A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
• A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
• Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
• TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer
• OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
• Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients
• Degarelix Neo-Adjuvant Radical Prostatectomy Trial
• GP Extended Action Triptorelin
• A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
• FACBC Outcomes for Post Prostatectomy
• Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
• An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
• A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
• A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
• TAK-700 in Castration Resistant Prostate Cancer
• Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
• 99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
• Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
• Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
• Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL)
• A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
• Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
• A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
• Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
• Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
• Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
• Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
• Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
• Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
• Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
• Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
• A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
• Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
• A Phase I Study of LFA102 in Japanese Patients
• Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation
• Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
• Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
• External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
• Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
• A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
• Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
• Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
• Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
• Cabozantinib in Advanced Solid Malignancies
• Saw Palmetto: Symptom Management for Men During Radiation Therapy
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
• Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
• Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer
• XL-184+Abiraterone in Post-Chemo CRPC
• Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
• Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
• Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
• Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort
• Study of Metformin With Simvastatin for Men With Prostate Carcinoma
• Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
• Second-line Chemotherapy in Castration Resistant Prostate Cancer
• Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy
• AMG 386 and Abiraterone for Advanced Prostate Cancer
• Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
• Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
• The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
• Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
• Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
• A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
• A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer
• Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
• Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
• Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
• A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer
• Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
• Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
• A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
• Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer
• Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
• Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
• Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
• Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant Chemotherapy in High Risk Prostate Cancer
• C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
• Response of Patients on Surveillance for Prostate Cancer to Dutasteride
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
• Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA
• BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)
• Tivantinib in Treating Patients With Metastatic Prostate Cancer
• Study of Weekly Cabazitaxel for Advanced Prostate Cancer
• A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
• Radiation and Androgen Ablation for Prostate Cancer
• Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
• The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
• Firmagon (Degarelix) Intermittent Therapy
• Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
• Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
• Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
• Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
• Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
• Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
• Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
• Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
• Tecemotide (L-BLP25) in Prostate Cancer
• Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
• Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
• The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer
• Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
• GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer
• Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
• Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
• Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
• Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer
• Oral Colchicine in Men With Castrate Resistant Prostate Cancer
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
• Pre-Prostatectomy Lovastatin on Prostate Cancer
• Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
• Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
• Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
• Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
• Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
• Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
• The Effects of Lycopene on High Risk Prostatic Tissue
• FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer
• Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
• Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
• Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
• Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
• Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
• Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
• A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
• Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
• GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
• Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
• Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
• Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
• Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
• Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
• Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
• Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy
• Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
• Trial of Modifications to Radical Prostatectomy
• A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer
• Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
• Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
• Phase II, Dose Finding Study of GTx-758
• BKM120 in Metastatic Castration-resistant Prostate Cancer
• Pazopanib, Docetaxel, Prednisone Prostate
• Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
• Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
• Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
• Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
• STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
• Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy
• EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
• Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
• An Open Label Prostate Cancer Study in Japanese Patients
• Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
• Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
• Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
• Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
• Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
• Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
• A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
• Economic Analyses of the REDUCE Trial
• Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
• A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
• Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
• Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
• Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
• A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
• BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
• Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
• Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
• Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
• IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
• Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
• Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
• Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.
• S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
• Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
• Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
• PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma
• Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
• A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
• 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
• Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
• Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
• Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
• A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
• PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers
• A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
• A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
• A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
• Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
• Saracatinib in Treating Patients With Prostate Cancer
• Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation
• A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
• Study to Find Maintenance Dose for Periodic Administration of ASP3550
• Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
• Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
• Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
• Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients
• Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
• Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
• BR55 in Prostate Cancer: an Exploratory Clinical Trial
• International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
• Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
• Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
• Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
• A Degarelix Trial in Patients With Prostate Cancer
• Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• F-18 Sodium Fluoride in Prostate Cancer
• A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
• Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
• Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer
• A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
• Sulforaphane in Treating Patients With Recurrent Prostate Cancer
• Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy
• Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
• A Study of Degarelix in Taiwanese Patients With Prostate Cancer
• Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
• ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma
• Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
• Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
• Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
• Metformin in Castration-Resistant Prostate Cancer
• Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
• Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-assisted Laparoscopic Radical Prostatectomy
• CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)
• PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
• PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
• A Study of Olaratumab (IMC-3G3) in Prostate Cancer
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
• Abiraterone Post Ketoconazole for Prostate Cancer
• Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
• TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
• Neoadjuvant Ipilimumab in Prostate Cancer
• Dutasteride in Treating Patients With Prostate Cancer
• Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
• Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
• A Study of PNT2258 in Patients With Advanced Solid Tumors
• Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
• Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
• A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer
• Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer
• GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
• High Risk Prostate Cancer Prevention Study
• Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
• Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
• Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
• Window Study of ZD4054 in Metastatic Prostate Cancer
• Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
• Open Label Prostate Cancer Study
• Digoxin for Recurrent Prostate Cancer
• Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
• Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
• Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
• Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
• Evaluate Recovery of Testosterone for Patients Using Eligard
• Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
• Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer
• OGX-427 in Castration Resistant Prostate Cancer Patients
• Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
• ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer
• Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)
• A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
• L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors
• A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
• Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
• Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide
• A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
• Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
• Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
• Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy
• A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
• A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer
• Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
• A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
• Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
• Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer
• Vitamin C as an Anti-cancer Drug
• Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
• Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
• Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
• SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
• A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
• Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
• Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
• Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
• Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy
• Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
• Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
• Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
• Ketoconazole and Dexamethasone in Prostate Cancer
• Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness
• Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
• Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
• Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
• Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
• A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
• Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer
• Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
• Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
• A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
• Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
• A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
• A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer
• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
• Study Evaluating the Safety and Tolerability of L-377202
• Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
• Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer
• Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
• Study Using WST11 in Patients With Localized Prostate Cancer
• Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunt
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
• Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers
• Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
• A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
• Efavirenz in Treating Patients With Metastatic Prostate Cancer
• ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
• Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15
• Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
• Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
• Post-operative or Early Salvage XRT and ADT for High Risk PCa
• A Trial of Degarelix in Patients With Prostate Cancer
• Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
• Effects of Sulforaphane on Normal Prostate Tissue
• Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
• Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
• A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
• Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
• Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
• S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
• Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
• Lenalidomide and Paclitaxel in Prostate Cancer
• Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
• A Study of Degarelix in Patients With Prostate Cancer
• Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
• Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer
• Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
• A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
• Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
• Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
• Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
• Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate
• Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
• Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
• FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
• Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
• Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
• An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate
• SonoVue Guided Prostate Biopsy
• A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
• Androcur Effects on Quality of Life
• Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
• Open Label Study of Sipuleucel-T
• Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
• Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy
• Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
• Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
• Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
• A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
• Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation
• Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
• Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
• ARI103094-Follow-Up Study for REDUCE Study Subjects
• A Study of Pre-operative Metformin in Prostate Cancer
• Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
• Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
• BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets
• Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study
• MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
• Study of Immunotherapy to Treat Advanced Prostate Cancer
• Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer
• Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
• 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
• Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
• Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer
• Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
• Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
• Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer
• Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
• Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
• Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
• TKI258 in Castrate Resistant Prostate Cancer
• Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
• Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
• The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer
• Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer
• Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients
• An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
• Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c
• Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
• Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)
• Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer
• A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
• Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
• C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
• Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
• Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer
• Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
• Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy
• BN83495 in Prostate Cancer
• Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy
• Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
• A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
• Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia
• White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
• Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
• Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
• Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
• AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
• Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
• Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
• Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
• PHA-739358 for Treatment of Hormone Refractory Prostate Cancer
• A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel
• A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
• Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
• Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer
• Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
• An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
• Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
• Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
• Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy
• Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
• Multimodality Phase II Study in Prostate Cancer
• Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer
• Open-Label, Randomised Parallel-Group Study
• Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
• Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer
• Natural Killer Cells and Bortezomib to Treat Cancer
• A Phase I/II Study of HE3235 in Patients With Prostate Cancer
• Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients
• Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents
• Study of WST11 in Patients With Localized Prostate Cancer
• MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
• A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
• Phase II Study of BI 2536 in Prostate Cancer
• Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer
• CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
• A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
• Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.
• PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
• Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
• A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
• An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
• Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
• Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases
• Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
• Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
• Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
• Botulinum Toxin Injection With Prostate Brachytherapy
• Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
• Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer
• Green Tea Extract and Prostate Cancer
• Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
• A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients
• (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
• Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer
• Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
• Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
• A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
• A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
• Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
• Herbal Therapy for Treatment of Recurrent Prostate Cancer
• Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
• Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
• Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
• Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
• PK in Pts With HRPC & Skeletal Metastes
• BAY88-8223, Does Response Study in HRPC Patients
• Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
• Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
• R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
• Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer
• A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
• Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
• Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
• Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
• Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer
• Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
• Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
• Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy
• Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer
• Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
• A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
• A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
• Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
• Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
• Casodex - Nolvadex Combination
• Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
• Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
• Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
• Open Label Trial to Assess Iressa in Prostate Cancer Patients
• Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)
• Satraplatin and Prednisone to Treat Prostate Cancer
• Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
• A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer
• Active Surveillance, Radical Prostatectomy, or Radiation Therapy in Treating Patients With Localized Prostate Cancer
• Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
• Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
• RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
• RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
• Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
• A Study of Leuprolide to Treat Prostate Cancer
• Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
• Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
• Brassica Vegetables or Indole-3-Carbinol in Treating Patients With PSA Recurrence After Surgery for Prostate Cancer
• A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
• Phase II Sunitinib Prog Met AIPC
• Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate
• Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
• Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy
• Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
• Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
• Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
• [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
• Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
• Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
• Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
• Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.
• Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
• Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
• Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury
• Testosterone in Castration-Resistant Prostate Cancer
• Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
• Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
• Statin Therapy Versus Placebo Prior to Prostatectomy
• A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
• Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
• Safety Study of TAK-700 in Subjects With Prostate Cancer.
• Phase II Study of ASP3550 in Patients With Prostate Cancer
• Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Ca
• A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
• FACBC PET/CT for Recurrent Prostate Cancer
• Efficacy Study of ABR-215050 to Treat Prostate Cancer
• Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
• Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer
• ARTS - AVODART After Radical Therapy For Prostate Cancer Study
• Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
• A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer
• Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
• Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.
• Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer
• Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer
• Sutent Maintenance After Response to Taxotere
• Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer
• Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
• Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
• An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
• ED Recovery in Men Age
• Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
• Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)
• Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
• An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
• Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
• Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
• Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
• Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
• Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer
• Brachytherapy for Prostatic Carcinoma Patients
• A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer
• Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
• Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
• Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
• Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
• Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
• Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
• AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
• Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer
• A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
• Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
• An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
• AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
• Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
• Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
• Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Laparoscopic Radical Prostatectomy
• A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
• Sandostatin for Patients With Androgen Independent Prostate Cancer
• A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
• Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
• Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
• Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
• E3-Hormone Refractory Prostrate Cancer Taxotere Combination
• Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
• Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
• Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
• Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)
• The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
• Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
• An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
• Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
• Intensity-Modulated Radiation Therapy, Docetaxel, and Hormone Therapy in Treating Patients With High-Risk Locally Advanced Prostate Cancer With Pelvic Lymph Node Metastasis
• Docetaxel in Treating Patients With Relapsed Prostate Cancer
• Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance
• Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy
• A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence
• A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer
• A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
• ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
• Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
• Fulvestrant in Hormone Refractory Prostate Cancer
• An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
• Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
• A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
• ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
• OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
• Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
• Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
• Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
• A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
• Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
• Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
• A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
• Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate
• The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
• Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
• Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer
• Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer
• Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
• The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
• Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
• A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
• Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)
• Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer
• Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
• Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer
• Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
• A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer
• Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
• Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
• Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
• Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
• Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer
• Study On Lidocaine Vs. Placebo Pain Control During Transrectal Ultrasound Guided Prostate Biopsy
• Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
• Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
• Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
• AZD2171 to Treat Prostate Cancer
• Taxotere Prostate Cancer New Indication Registration Trial in China
• Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
• A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer
• Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
• Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
• Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
• Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
• PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
• Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
• Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
• Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
• Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
• Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy
• Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer
• XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
• Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
• ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
• Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
• Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
• Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients
• Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
• Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
• Study of ATN-224 in Patients With Prostate Cancer
• Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer
• Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
• A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
• GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
• Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer
• Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer
• Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone
• Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer
• Maintaining Bone Strength in Men With Prostate Cancer
• Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
• Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
• External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
• A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
• Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
• Vidaza to Restore Hormone Thx Prostate
• A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
• Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer
• A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
• PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
• 131-I-TM-601 Study in Adults With Solid Tumors
• A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
• Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
• Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
• Investigation of Early Hormonotherapy Efficacy of Prostate Cancer
• Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
• MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
• Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
• Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
• Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
• Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer
• Soy Protein/Effexor Hormone Therapy for Prostate Cancer
• ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
• Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
• Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
• Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
• Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
• BAY88-8223, Dose Finding Study in Patients With HRPC
• Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
• Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
• Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
• Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
• Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
• Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
• Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
• Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
• Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
• A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer
• Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
• Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
• Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
• Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
• Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
• Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
• Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
• Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
• Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer
• PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
• A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
• Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy
• Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
• Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
• Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
• Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy
• Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
• Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure
• Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy
• Prostate Adenocarcinoma TransCutaneous Hormones
• MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)
• Study of SU11248 in Men With Advanced Prostate Cancer
• Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
• The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
• Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy
• ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
• Casodex/Zoladex Biomarkers in Localised Prostate Cancer
• FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer
• Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
• PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone
• Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
• A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
• Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
• Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
• Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
• Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer
• Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
• Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
• Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
• Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
• Metronomic Oral Vinorelbine in Patients With Metastatic Tumors
• Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
• GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
• DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
• Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
• Effects of GCP on Prostate Cancer.
• Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
• Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
• Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer
• Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
• Trial of Iressa in Prostate Cancer Patients
• Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
• Study of Oxaliplatin and Taxotere in Prostate Cancer
• Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
• Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
• Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
• A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
• Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
• CMAB vs IMAB in Metastatic Prostate Cancer
• Role of Soy Supplementation in Prostate Cancer Development
• A Study of Imatinib and Docetaxel in Prostate Cancer
• Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
• Study of Aranesp to Treat Anemia in Prostate Cancer Patients.
• Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy
• Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
• Fulvestrant in Treating Patients With Advanced Prostate Cancer
• Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
• Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer
• Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
• Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
• Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
• Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
• Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
• Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
• Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
• Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
• Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
• An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
• Effects of ASA on Prostate Tissue
• Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
• Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
• Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
• Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
• Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers
• Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone
• A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
• Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
• Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
• A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
• Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
• Fulvestrant in Treating Patients With Recurrent Prostate Cancer
• Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
• Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
• Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer
• An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
• Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
• Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?
• A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
• PROSTACOX : Metastatic Prostate Chemotherapy
• Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
• Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy
• An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
• Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health
• Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
• A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients
• Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
• RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
• Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
• Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
• Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
• Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation
• A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
• Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
• Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.
• Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
• Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
• Trilostane for Androgen-Independent Prostate Cancer
• Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
• Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
• A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
• Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)
• Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
• Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
• Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
• Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
• Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer
• Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
• Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
• Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
• A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
• The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
• Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
• Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer
• Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
• Exisulind Prior to Radical Prostatectomy
• Exisulind Versus Placebo After Surgical Removal of the Prostate
• Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
• A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
• Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy
• Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
• Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
• Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
• Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
• Tetrathiomolybdate in Hormone Refractory Prostate Cancer
• Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
• A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast
• ET 743 (Yondelis) in Men With Advanced Prostate Cancer
• Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
• Mifepristone (RU-486) in Androgen Independent Prostate Cancer
• Psychostimulants for Fatigue in Prostate Cancer
• Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy
• Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
• Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer
• Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
• A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
• Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
• Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
• S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
• Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
• Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer
• Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
• Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
• Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
• A Long Term Safety Study With Atrasentan
• Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
• Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients
• Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer
• Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
• A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer
• Cilengitide in Treating Patients With Prostate Cancer
• Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
• Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
• 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
• Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
• Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
• Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
• A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
• A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
• Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
• Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
• Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
• Vaccine and Antibody Treatment of Prostate Cancer
• Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
• Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
• Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
• Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
• A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
• Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer
• Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
• A Research Study for Patients With Prostate Cancer
• Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
• Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
• Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
• Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
• Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
• The Plenaxis® Experience Study
• Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
• Cilengitide in Treating Patients With Metastatic Prostate Cancer
• Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
• Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
• Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
• A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therap
• SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
• Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
• Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer
• Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
• A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
• Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy
• ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
• GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
• AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
• Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
• Study of Individualized Amonafide to Treat Prostate Cancer
• A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
• Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer
• GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
• Ixabepilone in Treating Patients With Metastatic Prostate Cancer
• Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
• Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
• Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
• Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
• Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
• Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
• Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
• Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
• Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
• Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
• Study of CEP-701 in Treatment of Prostate Cancer
• Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
• Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
• Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer
• Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
• Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
• Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
• Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
• Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer
• Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
• Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer
• Clinical Trial for Prostate Cancer
• CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
• GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
• Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
• Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
• A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
• Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
• MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
• A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy
• Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
• Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
• Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
• The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
• Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer
• ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
• Sequential Vaccinations in Prostate Cancer Patients
• Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
• Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
• Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
• Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
• Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
• Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
• Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
• Perifosine in Treating Patients With Recurrent Prostate Cancer
• Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
• Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
• Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer
• Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
• Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
• A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
• Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy
• Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
• 3-AP in Treating Patients With Advanced Prostate Cancer
• Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
• A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
• Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
• Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
• YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
• Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
• Prevention of Osteoporosis in Men With Prostate Cancer
• YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
• Atrasentan in Treating Patients With Prostate Cancer
• Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
• Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
• R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
• ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
• Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
• Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
• BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
• Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
• Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer
• Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
• Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
• Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
• Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
• Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
• Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
• Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
• Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
• A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
• Study Using CP-461 to Treat Advanced Prostate Cancer
• Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
• EPO906 Therapy in Patients With Prostate Cancer
• Ketoconazole Plus Docetaxel to Treat Prostate Cancer
• Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
• S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate
• Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
• S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
• Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer
• Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
• MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
• SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
• Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
• ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
• DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
• Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
• SU006668 in Treating Patients With Advanced Solid Tumors
• Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
• Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
• Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
• Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
• Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
• Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
• Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
• Flavopiridol in Treating Patients With Refractory Cancer
• Calcifidol Therapy in Men With Cancer
• Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
• Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
• Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
• BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
• Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
• Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
• Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
• CCI-779 in Treating Patients With Prostate Cancer
• Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
• Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
• S0000 Selenium and Vitamin E in Preventing Prostate Cancer
• A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
• Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
• Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate
• Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
• Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
• Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy
• Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
• Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
• SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
• Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
• PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer
• Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
• R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
• Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
• Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
• Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
• Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
• Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
• Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
• Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
• Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer
• Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
• Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
• Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
• Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
• Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
• EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
• Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
• S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
• Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
• Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
• Chemotherapy in Treating Patients With Prostate Cancer
• CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
• Liposomal Doxorubicin in Treating Patients With Prostate Cancer
• S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
• Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
• Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence
• Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer
• Docetaxel in Treating Patients With Stage IV Prostate Cancer
• Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
• Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
• Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer
• Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
• Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
• Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
• Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
• Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
• Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
• Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
• Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer
• Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
• Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer
• Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
• Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
• Hormone Therapy in Treating Patients With Prostate Cancer
• Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
• Vinorelbine in Treating Patients With Metastatic Prostate Cancer
• Flavopiridol in Treating Patients With Recurrent Prostate Cancer
• Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
• Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer
• Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
• Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
• Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy
• Chemotherapy in Treating Patients With Solid Tumors
• Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
• Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
• Hormone Therapy in Treating Patients With Advanced Prostate Cancer
• Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
• Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
• Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
• Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
• Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
• Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
• Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
• Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
• Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors
• SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
• Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
• Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
• Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
• A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
• A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
• A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma